US-based Lubrizol Corporation has acquired Particle Sciences, a compatriot contract drug developer and manufacturer headquartered at Bethlehem, Pennsylvania. Terms of the acquisition were not disclosed.

The Wickliffe, Ohio-based firm said the takeover of Particle Science will boost its pharmaceutical development capabilities in the life sciences, providing full service drug delivery solutions to the market across a variety of dosage forms.

Lubrizol is regarded as a global leader in complex formulations, including drug eluting device product development and sterile and particulate drug products.

“With the addition of Particle Sciences and the recent acquisition of Vesta, we are now able to offer customers a complete solution that is one of the most comprehensive in the industry," said Deb Langer, vice president and general manager, Lubrizol LifeSciences.

The Particle Sciences acquisition also will allow the Ohio company to leverage its core polymer chemistry to deliver tailored solutions for novel implantable and dermal drug delivery systems for improved patient outcomes, Langer said.

In the recent past, Lubrizol LifeSciences has significantly expanded its capabilities in the drug delivery market through new products, state-of-the-art facilities, acquisitions and alliances. The company has worked together with Particle Sciences for several years, providing various elements of an end-to-end solution from polymer supply through formulation and commercial manufacturing.

While being integrated into Lubrizol Advanced Materials, Particle Sciences will retain its company name.